



Research and Development

A Dynamic Pipeline


Daiichi Sankyo is committed to creating first-in-class and best-in-class therapies, and delivering these innovations as quickly and efficiently as possible to clinicians and patients who need them. In working towards this goal, we focus on our four core disease areas; thrombotic disorders, malignant neoplasm, diabetes mellitus and autoimmune diseases/rheumatoid arthritis, as well as the three franchise areas of hypertension, hyperlipidemia/atherosclerosis and bacterial infections.

Our R&D Division views its commitment through a “bench to bedside” lens, with a focus on efficiently translating our basic research findings into compounds with enormous therapeutic potential. Our pre-clinical, clinical and regulatory programs are designed to streamline the journey from discovery to development and approval. The Pharmaceutical Technology Division oversees the manufacture and supply of drug substances and products for clinical and non-clinical studies globally.



Products in Development

(as of July 31, 2009)



* Developed only in Japan

For the latest information on Daiichi Sankyo's R&D pipeline, please visit our website at:

www.daiichisankyo.com/ir/archive/index.html

A Legacy of Innovation

Daiichi Sankyo boasts a strong history of innovation and success in R&D, including our discovery and marketing of the first statin—a class of drug that transformed the treatment of hyperlipidemia and cardiovascular disease—as well as one of the first in a new and powerful class of anti-infectives.

In 1989, we launched *Pravastatin* (Mevalotin®) in Japan as the world's first water soluble, HMG-CoA reductase inhibitor, which has been used by millions of patients in more than 100 countries to treat hyperlipidemia. Similarly, the antihypertensive agent *Olmесartan medoxomil* (Olmotec® in Japan and Europe and Benicar® in the U.S.) is an angiotensin II receptor blocker (ARB) and proved to be highly effective in lowering blood pressure. Launched in the United States and Germany in 2002 and in Japan in 2004, *Olmесartan medoxomil* is helping patients in the treatment of hypertension in more than 50 countries improve and manage their health.

First launched in Japan in 1993, *Levofloxacin* (Cravit® in Japan, Levaquin® in the U.S. and Tavanic® in Europe) is one of the most trusted quinolones used in more than 120 countries. *Levofloxacin* is widely regarded among physicians because of its powerful antibacterial performance and broad-spectrum coverage against numerous diseases, accompanied with proven safety.